Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis
Pardeep S. Jhund, Atefeh Talebi, Alasdair Henderson, et al.
The Lancet (2024) Vol. 404, Iss. 10458, pp. 1119-1131
Open Access | Times Cited: 31

Showing 1-25 of 31 citing articles:

Cardiorenal syndrome: clinical diagnosis, molecular mechanisms and therapeutic strategies
Bo Zhao, Xinrong Hu, Weidong Wang, et al.
Acta Pharmacologica Sinica (2025)
Closed Access | Times Cited: 4
Albuminuria in Cardiovascular, Kidney, and Metabolic Disorders: A State-of-the-Art Review
Sophie E. Claudel, Ashish Verma
Circulation (2025) Vol. 151, Iss. 10, pp. 716-732
Closed Access | Times Cited: 3
Novel pharmacological approaches to lowering blood pressure and managing hypertension
Matthew Sayer, David J. Webb, Neeraj Dhaun
Nature Reviews Cardiology (2025)
Closed Access | Times Cited: 1
Cardiovascular–Endocrine–Metabolic Medicine: Proposing a New Clinical Sub-Specialty Amid the Cardiometabolic Pandemic
Nikolaos Theodorakis, Maria Nikolaou, Andrew J. Krentz
Biomolecules (2025) Vol. 15, Iss. 3, pp. 373-373
Open Access | Times Cited: 1
Heart Failure in Older Patients: An Update
Massimo Montalto, Federica D’Ignazio, Sara Camilli, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 6, pp. 1982-1982
Open Access | Times Cited: 1
JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
Takeshi Kitai, Shun Kohsaka, Takao Kato, et al.
Journal of Cardiac Failure (2025)
Closed Access | Times Cited: 1
The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial
Parminder K. Judge, Katherine R. Tuttle, Natalie Staplin, et al.
Nephrology Dialysis Transplantation (2024)
Open Access | Times Cited: 5
Finerenone in Women and Men With Heart Failure With Mildly Reduced or Preserved Ejection Fraction
Misato Chimura, Xiaowen Wang, Pardeep S. Jhund, et al.
JAMA Cardiology (2024)
Open Access | Times Cited: 4
Effect of Finerenone in Cardiovascular and Renal Outcomes: A Systematic Review and Meta-analysis
Juan Carlos Rivera-Martinez, Michael Sabina, Aqeel Khanani, et al.
Cardiovascular Drugs and Therapy (2025)
Open Access
Unentangling Heart Failure From Kidney Outcomes With Finerenone
Sanjay Kaul, Swapnil Hiremath
Journal of the American College of Cardiology (2025) Vol. 85, Iss. 2, pp. 169-172
Closed Access
SGLT2 Inhibitors: The First Endothelial-Protector for Diabetic Nephropathy
Davide Viggiano, Rashmi Joshi, Gianmarco Borriello, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 4, pp. 1241-1241
Open Access
Clinical utility and safety of finerenone in patients with heart failure: Rationale and design of FINE registry
Gonzalo Luis Alonso Salinas, Amaia Martínez León, David A. Cano, et al.
ESC Heart Failure (2025)
Open Access
Importance of early diagnosis and implementation of guideline-directed therapies in heart failure: a message worth repeating, but we need to act!
Camilla Hage, Angiza Shahim
Heart (2025), pp. heartjnl-325649
Closed Access
Eplerenone, diabetes, and chronic kidney disease in patients hospitalized for acute heart failure: findings from the EARLIER trial
Masatake Kobayashi, Akira Yamashina, Kazuhiro Satomi, et al.
Cardiovascular Diabetology (2025) Vol. 24, Iss. 1
Open Access
Finerenone and Atrial Fibrillation in Heart Failure
Shingo Matsumoto, Alasdair Henderson, Pardeep S. Jhund, et al.
JAMA Cardiology (2025)
Closed Access
Mode of Death in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction
Akshay S. Desai, Pardeep S. Jhund, Muthiah Vaduganathan, et al.
JAMA Cardiology (2025)
Closed Access
Obesity and heart failure—the role of GLP-1 receptor agonists
Gregor Simonis, Ulrike Schatz
Herz (2025)
Closed Access
Aldosterone-targeted therapies: early implementation in resistant hypertension and chronic kidney disease
Masatake Kobayashi, Bertram Pitt, João Pedro Ferreira, et al.
European Heart Journal (2025)
Open Access
Weekly Journal Scan: a deep insight into aldosterone antagonism across the heart failure spectrum
Daniela Pedicino, Massimo Volpe
European Heart Journal (2025)
Closed Access
The use of left ventricular ejection fraction in the diagnosis and management of heart failure. A clinical consensus statement of the Heart Failure Association (HFA) of the ESC, the Heart Failure Society of America (HFSA), and the Japanese Heart Failure Society (JHFS)
Giuseppe M.C. Rosano, John R. Teerlink, Koichiro Kinugawa, et al.
European Journal of Heart Failure (2025)
Closed Access
The use of Left Ventricular Ejection Fraction in the Diagnosis and Management of Heart Failure. A Clinical Consensus Statement of the Heart Failure Association (HFA) of the ESC, the Heart Failure Society of America (HFSA), and the Japanese Heart Failure Society (JHFS)
Giuseppe Rosano, John R. Teerlink, Koichiro Kinugawa, et al.
Journal of Cardiac Failure (2025)
Closed Access
The interplay between heart failure and chronic kidney disease
Anuradha Lala, Adeera Levin, Kamlesh Khunti
Diabetes Obesity and Metabolism (2025)
Open Access
A Prospective Crossover Clinical Trial of Esaxerenone and Eplerenone in Patients with Chronic Heart Failure Complicated by Hypertension
Akira Sezai, Masanori Abe, Takashi Maruyama, et al.
Life (2025) Vol. 15, Iss. 5, pp. 741-741
Open Access
Use of finerenone in patients with chronic kidney disease at high risk of heart failure
J Hakim, Yehuda Handelsman, Trina Banerjee
Metabolism (2025), pp. 156297-156297
Closed Access
The effects of SGLT2i on cardiac metabolism in patients with HFpEF: Fact or fiction?
Francesca Cinti, Renzo Laborante, Luigi Cappannoli, et al.
Cardiovascular Diabetology (2025) Vol. 24, Iss. 1
Open Access
Page 1 - Next Page

Scroll to top